Freeline Hemophilia B Gene Therapy May Have Advantage Over Competitors
Almost No Patients Required Post-Treatment Factor Replacement Therapy
UniQure has a potential first-mover advantage, but Freeline study's investigator compares FLT180a to later model smartphones with bugs fixed.
